تصفح COVID-19 Research حسب المؤلف "Abu Raddad, Laith J."
السجلات المعروضة 1 -- 20 من 26
-
All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
( BMJ Publishing Group , 2023 , Article)Objective To investigate all-cause mortality, COVID-19 mortality and all-cause non-COVID-19 mortality in Qatar during the COVID-19 pandemic. Methods A national, retrospective cohort analysis and national, matched, retrospective ... -
Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics
( springer nature , 2022 , Article)Background: Prospective observational data show that infected persons with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain polymerase chain reaction (PCR) positive for a prolonged duration, and that ... -
Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
( MDPI , 2022 , Report)The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was ... -
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
( NLM (Medline) , 2021 , Article)BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed ... -
Associations of Vaccination and of Prior Infection with Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar
( American Medical Association , 2021 , Article)The SARS-CoV-2 pandemic has severely affected international travel. With efficacious COVID-19 vaccines available, Qatar implemented a pilot program between February 18 and April 26, 2021, to ease travel restrictions by ... -
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
( springer nature , 2021 , Article)The overarching objective of this study was to provide the descriptive epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by addressing specific research questions through a ... -
Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting
( Elsevier , 2024 , Article)BackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy ... -
Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants
( Elsevier , 2022 , Article)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly evolving RNA virus that mutates within hosts and exists as viral quasispecies. Here, we evaluated the within-host diversity among vaccinated and ... -
Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant
( NLM (Medline) , 2022 , Article)SHORT SUMMARY: Severe acute respiratory syndrome coronavirus 2 infection from the Omicron variant in children/adolescents is less severe than infection from the Delta variant. Those 6 to <18 years also have less severe ... -
COVID-19 Disease Severity in Persons Infected with Omicron BA.1 and BA.2 Sublineages and Association with Vaccination Status
( American Medical Association , 2022 , Article)Infection with the SARS-CoV-2 Omicron variant is associated with less severe disease compared with the Delta variant.1-3 Two main Omicron sublineages—BA.1 and BA.2—have variable geographic distribution. In Qatar, BA.1 was ... -
Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
( Massachusetts Medical Society , 2022 , Article)The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ... -
Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals
( MDPI , 2020 , Article)Abstract: To support the deployment of serology assays for population screening during the COVID-19 pandemic, we compared the performance of three fully automated SARS-CoV-2 IgG assays: Mindray CL-900i® (target: spike [S] ... -
Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
( Oxford University Press , 2022 , Article)The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ... -
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
( Nature Research , 2022 , Article)SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ... -
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
( Massachusetts Medical Society , 2022 , Article)Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ... -
Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
( Elsevier , 2023 , Article)BackgroundSome studies have reported that influenza vaccination is associated with lower risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) morbidity ... -
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
( Elsevier , 2022 , Article)ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe ... -
Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
( Frontiers Media , 2022 , Article)In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy ... -
Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
( Elsevier , 2023 , Article)BackgroundEvidence on the effectiveness of vaccination-induced immunity compared to SARS-CoV-2 natural immunity is warranted to inform vaccination recommendations. AimIn this study, we aimed to conduct a comparative ... -
Low risk of serological cross-reactivity between the dengue virus and SARS-CoV-2 IgG antibodies using advanced detection assays.
( Karger , 2022 , Report)Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point of care (POC) rapid testing kits. However, some rapid ...
